Sabcs 2012

[Rolepaul]

Great sessions! I did not have Time Off this time, but I should next year. I might even end up working in Texas from my looking around.

[vonny]

Thank you Rhondalea for the link and info, it does help to make sense of it all.

[mamacze]

Lani, the time you take; digesting and passing along the vital bits, has helped so many of us. You just keep paying forward and forward. I can only imagine the spiraling positive effects of all your efforts. I too had adjacent DCIS. Your abstracts are like one big bucket full of hope. Thank you so much.
Love Kim from CT

[Pray]

Lani, You are always a constant source of good news " New Hope!" You are so appreciated dearly.

Peace,

Nancy

[Paula O]

Program Overview
2012 San Antonio Breast Cancer Symposium*
December 4-8, 2012 | San Antonio, Texas
This independent educational program contains comprehensive, yet concise summaries and expert analysis of the key studies presented at the 2012 San Antonio Breast Cancer Symposium.

http://www.clinicaloptions.com/Oncol...ec%202012.aspx

['lizbeth]

RhondaLea,

Thanks for filling my morning with levity. I love the clever gene names!

[Paula O]

Lani,

It looks like you aren't reachable with a PM--I tried. I hope I am not being too bold to ask: I wondered if you possibly would be willing to help me decipher the take away info in layman's terms on the Mini Symposium 2: Breast Density: Mechanisms and Clinical Implications. Are you a scientist? Did you listen in on that session and were you in the mentoring session that evening? I asked my questions to the medical panel during that evening mentorring session . I felt that they gave a good overview of Dr Tisty's lecture and limits in the clinical implications but honestly I could use some help making headway in understanding and explaining the charts, graphs, etc on the basic genetics, epidemilogy, and biology. I am finding it very complex and am supposed to write a 3-5 page paper about those three sessions for the Alamo Breast Cancer Foundation. Right now I am plowing through my 1 1/2 hours of fast and furious messy notetaking with the slides that are on line and looking up some past medical write ups on the implications of breast density, cancer, and survival. So far I'm not seeing any news articles about the research in that particular session to glean from but read the one that was published in November (that you posted here) about the legislation and legal mandates in some states requiring radiologists to notify women of their breast density and possible increased cancer risk. I printed out another 5-6 on-line articles on breast density to go through that I hope will be helpful in understanding the genetics and science from the symposium that I'm supposed to write about relating to breast density. Anyway, honestly alot of this stuff is above my head but I want to do a good job. I'm going to be in contact with a doc from the medical panel that have made themselves available to mentor us some in these write ups after I do some more work on my own but wondered if you could give me a hand on this as well before I contact them or point me to articles maybe I am not seeing that were written up after the 2012 symposium putting it into more understandable terms?

Of course no problem or pressure if it doesn't work out for you to help me--I thought it wouldn't hurt to ask and I would certainly appreciate it very much if you are able to give me a hand with understanding this better.
Thanks,

Paula

[Paula O]

http://www.curetoday.com/index.cfm/f...-breast-cancer (Brief video recap of presentations on Herceptin at 2012 SABCS)

One year of Herceptin optimal for HER2-positive breast cancer

BY DEBU TRIPATHY | DECEMBER 11, 2012
On one of the final days of SABCS there was some interesting updates to Herceptin.
Seven years ago, the original data on Herceptin in early-stage breast cancer was presented. This year, there was an interesting update to the U.S. trial that was presented. That confirmed that Herceptin is saving lives. We now have fewer deaths and fewer recurrences because of this drug. With longer follow-up, the certainty we have with the data is even greater.
Two studies looked at the duration of Herceptin. One study looked at giving Herceptin for two years and another study looked at giving it for less time, for six months. That trial found that results were worse, especially for patients given Herceptin after chemotherapy, which we usually don't do in the U.S. Here in the states, the drugs usually overlap. In that setting, when Herceptin is given for six months, the results were borderline statistically inferior, meaning one year still appears to be a little better than six months. But that's still important because 10 to 15 percent may have to discontinue Herceptin early because of side effects. These results make that decision a little easier knowing that six months of Herceptin still provides some benefit.

[Paula O]

Here is an article about SABCS highlights written by a breast cancer patient advocate that I met: <A href="http://womenwcancer.blogspot/" target=_blank>http://womenwcancer.blogspot.com